3 key trends shaping the immunology market

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

J&J faces FTC probe on Remicade biosimilar defence

J&J ends 2018 on a high, but coming year looks shaky

Johnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition to some of its top products starts to have an impact on revenues.

Stelara gains US approval for Crohn’s disease

New use for patients who fail anti-TNF drugs

No US Remicade biosimilar until at least October

Pfizer must wait until 180 day period ends, court fight ongoing.

Biosimilar switching not suitable for all patients

Antibodies against originator will also target biosimilar.